<!doctype html><html lang=en-us><head><script src="/livereload.js?mindelay=10&amp;v=2&amp;port=1313&amp;path=livereload" data-no-instant defer></script><meta charset=utf-8><meta http-equiv=X-UA-Compatible content="IE=edge"><meta name=viewport content="width=device-width,initial-scale=1,shrink-to-fit=no"><meta http-equiv=Content-Security-Policy content="default-src 'self'; script-src 'self' 'unsafe-inline' https://gc.zgo.at https://cdn.jsdelivr.net; style-src 'self' 'unsafe-inline'; img-src 'self' data: https:; font-src 'self' data:; connect-src 'self' https://philippdubach.goatcounter.com https://weekly-top-goatcounter-api.philippd.workers.dev https://newsletter-api.philippd.workers.dev https://gc.zgo.at https://pdub.click; frame-ancestors 'self'; base-uri 'self';"><link rel=preconnect href=https://gc.zgo.at crossorigin><link rel=preconnect href=https://static.philippdubach.com crossorigin><link rel=preconnect href=https://pdub.click crossorigin><link rel=preconnect href=https://newsletter-api.philippd.workers.dev crossorigin><link rel=dns-prefetch href=https://gc.zgo.at><link rel=dns-prefetch href=https://static.philippdubach.com><link rel=dns-prefetch href=https://pdub.click><link rel=dns-prefetch href=https://newsletter-api.philippd.workers.dev><meta name=robots content="index, follow"><title>GLP-1 Receptor Agonists in ASUD Treatment - philippdubach.com</title><meta name=description content="Research on GLP-1 agonists like semaglutide as potential treatments for alcohol dependency, with promising results from early trials."><meta name=keywords content="GLP-1 receptor agonists,semaglutide,alcohol dependency treatment,medical therapy research,healthcare innovation,pharmaceutical research,Ozempic,Novo Nordisk,randomized controlled trial,naltrexone,diabetes medication,clinical trials,healthcare solutions,GLP-1RA therapy"><meta name=author content="Philipp Dubach"><meta name=generator content="Hugo 0.149.0"><link rel=canonical href=http://localhost:1313/2025/11/21/glp-1-receptor-agonists-in-asud-treatment/><style></style><link rel=icon type=image/png href=/icons/favicon-96x96.png sizes=96x96><link rel=icon type=image/svg+xml href=/icons/favicon.svg><link rel="shortcut icon" href=/icons/favicon.ico><link rel=apple-touch-icon sizes=180x180 href=/icons/apple-touch-icon.png><meta name=apple-mobile-web-app-title content="philippdubach.com"><link rel=manifest href=/icons/site.webmanifest><meta name=theme-color content="#2c3e50"><meta name=msapplication-TileColor content="#2c3e50"><meta property="og:title" content="GLP-1 Receptor Agonists in ASUD Treatment"><meta property="og:description" content="Research on GLP-1 agonists like semaglutide as potential treatments for alcohol dependency, with promising results from early trials."><meta property="og:type" content="article"><meta property="og:url" content="http://localhost:1313/2025/11/21/glp-1-receptor-agonists-in-asud-treatment/"><meta property="og:site_name" content="philippdubach.com"><meta property="og:locale" content="en_US"><meta property="og:logo" content="http://localhost:1313/icons/favicon.ico"><meta property="og:image" content="https://static.philippdubach.com/ograph/ograph-glp1addiction.jpg"><meta property="og:image:secure_url" content="https://static.philippdubach.com/ograph/ograph-glp1addiction.jpg"><meta property="og:image:url" content="https://static.philippdubach.com/ograph/ograph-glp1addiction.jpg"><meta property="og:image:type" content="image/jpeg"><meta property="article:published_time" content="2025-11-21T00:00:00Z"><meta property="article:modified_time" content="2025-11-21T00:00:00Z"><meta property="article:section" content="posts"><meta name=twitter:card content="summary_large_image"><meta name=twitter:title content="GLP-1 Receptor Agonists in ASUD Treatment"><meta name=twitter:description content="Research on GLP-1 agonists like semaglutide as potential treatments for alcohol dependency, with promising results from early trials."><meta name=twitter:image content="https://static.philippdubach.com/ograph/ograph-glp1addiction.jpg"><meta name=twitter:image:src content="https://static.philippdubach.com/ograph/ograph-glp1addiction.jpg"><script type=application/ld+json>{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"http:\/\/localhost:1313\/"},{"@type":"ListItem","position":2,"name":"Posts","item":"http:\/\/localhost:1313\/posts/"},{"@type":"ListItem","position":3,"name":"GLP-1 Receptor Agonists in ASUD Treatment","item":"http:\/\/localhost:1313\/2025\/11\/21\/glp-1-receptor-agonists-in-asud-treatment\/"}]}</script><script type=application/ld+json>{"@context":"https://schema.org","@type":"Article","headline":"GLP-1 Receptor Agonists in ASUD Treatment","name":"GLP-1 Receptor Agonists in ASUD Treatment","description":"Research on GLP-1 agonists like semaglutide as potential treatments for alcohol dependency, with promising results from early trials.","keywords":["GLP-1 receptor agonists","semaglutide","alcohol dependency treatment","medical therapy research","healthcare innovation","pharmaceutical research","Ozempic","Novo Nordisk","randomized controlled trial","naltrexone","diabetes medication","clinical trials","healthcare solutions","GLP-1RA therapy"],"articleBody":"\" Alcohol and other substance use disorders (ASUDs) are complex, multifaceted, but treatable medical conditions with widespread medical, psychological, and societal consequences. However, treatment options remain limited, therefore the discovery and development of new treatments for ASUDs is critical. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently approved for the treatment of type 2 diabetes mellitus, obesity, and obstructive sleep apnea, have recently emerged as potential new pharmacotherapies for ASUDs.\\nThis development matters most for people struggling with substance use disorders who have few effective treatment options. It also matters for manufacturers like Novo Nordisk facing patent expiration pressures on Ozempic. The research into GLP-1RAs for addiction treatment is early but notable given the limited pharmacotherapy options currently available for ASUDs. In February 2025, researchers at UNC published results from the first randomized controlled trial of semaglutide for ASUD treatment. The phase 2 trial enrolled 48 non-treatment-seeking adults with AUD and administered low-dose semaglutide (0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks - standard dosing for weight loss reaches 2.4 mg per week) over 9 weeks. Participants on semaglutide consumed less alcohol in controlled laboratory settings and reported fewer drinks per drinking day in their normal lives. They also reported less craving for alcohol. Heavy drinking episodes declined more sharply in the semaglutide group compared to placebo over the nine-week trial. Despite the low doses, effect sizes for some drinking outcomes exceeded those typically seen with naltrexone, one of the few FDA-approved medications for alcohol use disorder. While larger trials are needed to confirm these results, the early evidence suggests GLP-1 may offer a meaningful treatment option for a condition where new therapies have been approved at a rate of roughly one every 25 years.\\n\"","wordCount":284,"inLanguage":"en","image":"https:\/\/static.philippdubach.com\/ograph\/ograph-glp1addiction.jpg","datePublished":"2025-11-21T00:00:00Z","dateModified":"2025-11-21T00:00:00Z","mainEntityOfPage":{"@type":"WebPage","@id":"http:\/\/localhost:1313\/2025\/11\/21\/glp-1-receptor-agonists-in-asud-treatment\/"},"publisher":{"@type":"Organization","name":"philippdubach","logo":{"@type":"ImageObject","url":"http:\/\/localhost:1313\/icons/favicon.ico"}},"author":{"@type":"Person","name":"Philipp Dubach"}}</script></head><body class=linkblog><div class=container><aside class=sidebar><div class=sidebar-content><div class=site-header><div class=site-title><a href=http://localhost:1313/>philippdubach</a></div><p class=site-description>Blog about Personal Projects, Articles and Papers on Economics, Finance and Technology</p></div><nav class=navigation><ul><li><a href=/>Home</a></li><li><a href=/projects/>Projects</a></li><li><a href=/posts/>Archive</a></li><li><a href=/about/>About</a></li><li><a href=/index.xml>RSS</a></li></ul></nav><div class=social-links><a href=https://github.com/philippdubach target=_blank rel=noopener>GitHub</a>
<a href=mailto:info@philippdubach.com>Email</a></div></div></aside><main class=content><article class="post single"><header class=post-header><h1 class=post-title>GLP-1 Receptor Agonists in ASUD Treatment</h1><div class=post-meta><time datetime=2025-11-21T00:00:00Z>November 21, 2025
</time>• 300 words
• 2 min read
• <a href=https://academic.oup.com/jes/article/9/11/bvaf141/8277723 target=_blank rel=noopener>via</a>
• <a href=# id=share-link title="Copy short link" aria-label="Copy short link" style=text-decoration:none>∞</a>
<span id=share-status></span></div></header><div class=post-content><blockquote><p>Alcohol and other substance use disorders (ASUDs) are complex, multifaceted, but treatable medical conditions with widespread medical, psychological, and societal consequences. However, treatment options remain limited, therefore the discovery and development of new treatments for ASUDs is critical. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently approved for the treatment of type 2 diabetes mellitus, obesity, and obstructive sleep apnea, have recently emerged as potential new pharmacotherapies for ASUDs.</p></blockquote><p>This development matters most for people struggling with substance use disorders who have few effective treatment options. It also matters for manufacturers like Novo Nordisk facing <a href=https://philippdubach.com/2025/06/29/novo-nordisks-post-patent-strategy/>patent expiration pressures on Ozempic</a>. The research into GLP-1RAs for addiction treatment is early but notable given the limited pharmacotherapy options currently available for ASUDs. In February 2025, researchers at UNC published results from the first randomized controlled trial of semaglutide for ASUD treatment. The phase 2 trial enrolled 48 non-treatment-seeking adults with AUD and administered low-dose semaglutide <a href=https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2829811>(0.25 mg/week for 4 weeks, 0.5 mg/week for 4 weeks - standard dosing for weight loss reaches 2.4 mg per week)</a> over 9 weeks. Participants on semaglutide consumed less alcohol in controlled laboratory settings and reported fewer drinks per drinking day in their normal lives. They also reported less craving for alcohol. Heavy drinking episodes declined more sharply in the semaglutide group compared to placebo over the nine-week trial. Despite the low doses, effect sizes for some drinking outcomes exceeded those typically seen with naltrexone, one of the few FDA-approved medications for alcohol use disorder. While larger trials are needed to confirm these results, the early evidence suggests GLP-1 may offer a meaningful treatment option for a condition where new therapies have been approved at a rate of roughly one every 25 years.</p></div></article><footer class=feedback-footer><p>Have feedback, comments, or ideas? <a href=mailto:info@philippdubach.com>I'd love to hear from you</a>.</p><p class=latest-post>Latest: <a href=/2025/12/27/book-review-why-machines-learn/>Book Review: Why Machines Learn</a></p><p class=most-read id=top-post-week style=min-height:1.5em></p></footer><script>(function(){var e,n,t=document.getElementById("top-post-week");if(t&&fetch("https://weekly-top-goatcounter-api.philippd.workers.dev").then(function(e){return e.ok?e.json():Promise.reject()}).then(function(e){if(e.hits&&e.hits.length>0){var n=e.hits[0];t.innerHTML='Most read: <a href="'+n.path+'">'+n.title.replace(" - philippdubach.com","")+"</a>"}else t.remove()}).catch(function(){t.remove()}),n=document.getElementById("share-link"),e=document.getElementById("share-status"),!n)return;n.addEventListener("click",function(t){t.preventDefault(),e.textContent="...";var s,n=window.location.href;navigator.clipboard&&navigator.clipboard.write&&typeof ClipboardItem!="undefined"?(s=new ClipboardItem({"text/plain":fetch("https://pdub.click/yourls-api.php?signature=4807288869&action=shorturl&format=json&url="+encodeURIComponent(n)).then(function(e){return e.json()}).then(function(e){var t=e.shorturl||"";return new Blob([t],{type:"text/plain"})}).catch(function(){return new Blob([""],{type:"text/plain"})})}),navigator.clipboard.write([s]).then(function(){e.textContent="url copied",setTimeout(function(){e.textContent=""},2e3)}).catch(function(){e.textContent="error",setTimeout(function(){e.textContent=""},2e3)})):fetch("https://pdub.click/yourls-api.php?signature=4807288869&action=shorturl&format=json&url="+encodeURIComponent(n)).then(function(e){return e.json()}).then(function(t){var n=t.shorturl;n&&navigator.clipboard&&navigator.clipboard.writeText?navigator.clipboard.writeText(n).then(function(){e.textContent="url copied",setTimeout(function(){e.textContent=""},2e3)}).catch(function(){e.textContent=n,setTimeout(function(){e.textContent=""},4e3)}):n?(e.textContent=n,setTimeout(function(){e.textContent=""},4e3)):(e.textContent="error",setTimeout(function(){e.textContent=""},2e3))}).catch(function(){e.textContent="error",setTimeout(function(){e.textContent=""},2e3)})})})()</script></main></div></body></html>